Alternatives to Tersavia
Tersavia is a Rare Disease tool: theravia is a pharmaceutical company specializing in therapies for rare and debilitating conditions. Here are the 60 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Rare Disease companies to Tersavia
- Website
Mironid59BiotechnologyGlasgow, United Kingdom$46.0MBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- Website
Immix Biopharma, Inc.51BiotechnologyLos Angeles, United States$5.0MA clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.
- Website
Moderna77BiotechnologyCambridge, United States$4.5BModerna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
- Website
Amgen34BiotechThousand Oaks, United States$40.0MA global biotechnology company discovering, developing, manufacturing, and delivering innovative human therapeutics.
- Website
Elicit62Artificial IntelligenceOakland, United States$31.0MAI-powered research assistant for scientific literature review and data extraction.
- Website
Degron Therapeutics62BiotechnologySan Diego, USA$40.0MClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
- Website
Algorithmiq60Quantum ComputingHelsinki, Finland$38.1MQuantum software company enabling breakthroughs in chemistry, materials science, and life sciences.
- Website
CellCentric60BiotechnologyCambridge, United Kingdom$375.0MA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
- Website
Infinimmune60BiotechnologyAlameda, United States$75.0MDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
- Website
Adcendo60BiotechnologyCopenhagen, Denmark$272.0MDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
- Website
Enterome60BiotechnologyParis, France$123.9MClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
- Website
Celerion59BiotechnologyLincoln, USA$45.0MA global leader in clinical pharmacology and bioanalytical sciences.
- Website
Spark Therapeutics58BiotechnologyPhiladelphia, United States$82.8MA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
- Website
Rocket Pharmaceuticals57BiotechnologyCranbury, USA$382.9MA biotechnology company developing genetic therapies for rare disorders.
- Website LŌLōkahi Therapeutics57BiotechnologyLa Jolla, USA$63.0M
A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.
- Website
KaliVir Immunotherapeutics, Inc.57BiotechnologyPittsburgh, United States$14.0MClinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.
- Website
Janux Therapeutics57BiotechnologySan Diego, USA$181.0MA clinical-stage biopharmaceutical company developing novel immunotherapies.
- EAEarendil Labs56BiotechnologyBeijing, China$787.0M
Earendil Labs is an AI biotechnology company focused on leveraging artificial intelligence for drug discovery and development of next-generation biologics.
- Website
Owkin56Artificial IntelligenceNew York, USA$80.0MAI company using federated learning to solve biological complexity and accelerate drug discovery.
- Website
Anagram Therapeutics55BiotechnologyNatick, USA$285.0MClinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.
Showing the 20 closest matches. See the rest on the Tersavia profile.